Evidence map›Paper›PMID 39845357›Full record

ArticleBrain & spine2025

PD-L1 expression in PitNETs: Correlations with the 2022 WHO classification.

Ethan Harel, Ekkehard Hewer, Stefano La Rosa, Jean Philippe Brouland, Nelly Pitteloud, Federico Santoni, Maxime Brunner, Roy Thomas Daniel, Mahmoud Messerer, Giulia Cossu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Brain & spine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ethan HarelDivision of Neurosurgery, Department of Clinical Neurosciences, University Hospital of Lausanne and University of Lausanne, Lausanne, Switzerland.
Ekkehard HewerDepartment of Laboratory Medicine and Pathology, Institute of Pathology, University of Lausanne, Lausanne, Switzerland.
Stefano La RosaUnit of Pathology, Department of Medicine and Technological Innovation, University of Insubria, Varese, Italy.
Jean Philippe BroulandDepartment of Laboratory Medicine and Pathology, Institute of Pathology, University of Lausanne, Lausanne, Switzerland.
Nelly PitteloudService of Endocrinology Diabetes and Metabolism, University Hospital of Lausanne and University of Lausanne, Lausanne, Switzerland.
Federico SantoniService of Endocrinology Diabetes and Metabolism, University Hospital of Lausanne and University of Lausanne, Lausanne, Switzerland.
Maxime BrunnerService of Endocrinology Diabetes and Metabolism, University Hospital of Lausanne and University of Lausanne, Lausanne, Switzerland.
Roy Thomas DanielDivision of Neurosurgery, Department of Clinical Neurosciences, University Hospital of Lausanne and University of Lausanne, Lausanne, Switzerland.
Mahmoud MessererDivision of Neurosurgery, Department of Clinical Neurosciences, University Hospital of Lausanne and University of Lausanne, Lausanne, Switzerland.
Giulia CossuDivision of Neurosurgery, Department of Clinical Neurosciences, University Hospital of Lausanne and University of Lausanne, Lausanne, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: and research question: Prognostic factors to predict the behavior of pituitary neuroendocrine tumors (PitNET) are scarce. PD-L1 expression was associated with prognosis in other neuroendocrine neoplasms and we analyzed PD-L1 expression in PitNET, according to the 2022 WHO classification. Material and methods: A retrospective analysis was performed. Immunohistochemistry was used to define PD-L1 expression, which was quantified as TPS (tumor proportion score). The primary outcome was to assess the correlation between PD-L1 expression and transcription factors (TF), namely T-pit, Pit-1, SF-1 and GATA-3. As secondary outcomes, we evaluated the association between PD-L1 expression and proliferation indexes. Results: Eighty-eight patients were included. The largest group belonged to the SF-1-lineage (48%), followed by tumors of the Pit-1 lineage (32%) and T-pit lineage (17%). PD-L1 expression was associated with Pit-1 expression (p < 0.001) and with the somatotroph, lactotroph and mammosomatotroph subgroups. A TPS ⩾35% showed a 100% sensitivity for the mammosomatotroph subtype, while the optimal cut-off point was 20% for somatotroph and 15% for lactotroph tumors. PD-L1 expression was negatively associated with SF-1 and GATA3 expression(p < 0.001), with an optimal cut-point ≤5%. No association was found between PD-L1 expression and immunohistochemical proliferative factors but PD-L1 expression was associated with female sex and a younger age at diagnosis. Conclusion: PD-L1 expression was associated with PIT-1 lineage, while it was downregulated in SF-1-lineage tumors. No correlation was found with proliferative factors. The role of PD-L1 expression in determining the biological behavior of PitNET remains debated and larger studies are necessary to further confirm these findings.

Indexed as

2022 WHO classification of PitNETsPD-L1Pit-NETsPituitary adenomaPituitary neuroendocrine tumorsTranscription factors

Identifiers

PMID39845357
PMCPMC11751414

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.